. "2011-04-27+02:00"^^ . . "1"^^ . "V\u00FDznam renin-angiotenzinov\u00E9ho syst\u00E9mu v patofyziologii inzulinov\u00E9 rezistence" . "1"^^ . . "0"^^ . . "1"^^ . "2008-12-31+01:00"^^ . . "Testov\u00E1n\u00ED vlivu akutn\u00ED in vivo navozen\u00E9 hyperinzulin\u00E9mie/nebo blok\u00E1dy AT1 receptor\u016F (losartan) na s\u00E9rov\u00E9 koncentrace a expresi gen\u016F vybran\u00FDch adipokin\u016F v subkut\u00E1nn\u00ED tukov\u00E9 tk\u00E1ni u nemocn\u00FDch s diabetem 2. typu a zdrav\u00FDch osob. Sledov\u00E1n\u00ED vlivu 3-t\u00FDdenn\u00ED blok\u00E1dy AT1 receptor\u016F (telmisartan) na IR a expresi vybran\u00FDch adipokin\u016F v subkut\u00E1nn\u00ED tukov\u00E9 tk\u00E1ni a jejich s\u00E9rov\u00E9 koncentrace u osob s metabolick\u00FDm syndromem a vyj\u00E1d\u0159enou poruchou gluk\u00F3zov\u00E9 tolerance." . "0"^^ . "insulin resistance" . . "insulin resistance; type 2 diabetes; adipokines; angiotensin II; sartans; glycaemic clamp"@en . . "In healthy men, an acute administration of losartan decreases TNFalpha and resistin and increases adiponectin during acute hyperinsulinemia. Treatment with telmisartan (3 weeks) has the similar advantages in patients with insulin resistance."@en . " sartans" . . "2008-03-05+01:00"^^ . "2006-01-01+01:00"^^ . . " type 2 diabetes" . . . "http://www.isvav.cz/projectDetail.do?rowId=NR8821"^^ . . "NR8821" . "Jednor\u00E1zov\u00E9 pod\u00E1n\u00ED losartanu u zdrav\u00FDch osob sni\u017Euje TNFalfa a rezistin a zvy\u0161uje adiponektin v podm\u00EDnk\u00E1ch akutn\u00ED hyperinsulinemie. L\u00E9\u010Dba telmisartanem (3 t\u00FDdny) m\u00E1 obdobn\u00E9 p\u0159\u00EDzniv\u00E9 \u00FA\u010Dinky u insulinresistentn\u00EDch osob."@cs . "Role of renin-angiotensin system in pathophysiology of insulin resistance"@en . . . . . . " angiotensin II" . " adipokines" . "To test in vivo the effect of acutely-induced hyperinsulinaemia/or AT receptor blockade (losartan) on plasma concentrations of selected adipokines and their expressions in subcutaneous adipose tissue in type 2 diabetes and healthy subjects. To test the effect of 3-week AT receptor blockade (telmisartan) on insulin resistance and expressions of selected adipokines in subcutaneous adipose tissue and their plasma concentrations in subjects with metabolic syndrome and impaired glucose tolerance"@en . .